Keros Therapeutics director proposes 574-share sale

Available on EDGAR 11/12/2026 - 04:02 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) director Anne Prener filed a notice of a proposed sale of 574 common shares, with an aggregate market value of $5,619 and an approximate sale date of November 12, 2026. UBS Financial Services Inc. is named as broker. The notice says the shares were acquired from the issuer through RSU vesting on August 15, 2026. It lists August 6, 2026, as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

Key Figures

Proposed sale: 574 shares Aggregate market value: $5,619 Common shares outstanding: 19,624,374 shares

3 metrics

Proposed sale 574 shares Anne Prener’s notice; approximate sale date November 12, 2026

Aggregate market value $5,619 Value reported for the proposed sale

Common shares outstanding 19,624,374 shares As reported in the notice

Key Terms

RSU Vesting, Rule 10b5-1

2 terms

RSU Vesting financial

"Nature of acquisition: RSU Vesting"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

Rule 10b5-1 regulatory

"Date of plan adoption or giving of instruction, if relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KROS shares did Anne Prener plan to sell, and when?

Anne Prener, a director of Keros Therapeutics, reported a proposed sale of 574 common shares, with an aggregate market value of $5,619 and an approximate sale date of November 12, 2026. UBS Financial Services Inc. is named as broker.

How did Anne Prener acquire the shares listed in the KROS sale notice?

The notice says the 574 shares were acquired from Keros Therapeutics through RSU vesting on August 15, 2026.

What Rule 10b5-1 date appears in Anne Prener’s KROS notice?

The notice lists August 6, 2026 as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001797917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Keros Therapeutics, Inc.
SEC File Number	001-39264
Address of Issuer	1050 WALTHAM STREET, SUITE 302 LEXINGTON MASSACHUSETTS 02421
Phone	617-314-6297
Name of Person for Whose Account the Securities are To Be Sold	Prener Anne
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave 4th Floor New York NY 10010	574	5619.00	19624374	11/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2026	RSU Vesting	Issuer			574	08/15/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Anne Prener
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)